$95.00
GLP-S is a 31-amino-acid glucagon-like peptide-1 (GLP-1) receptor agonist with 94% homology to native GLP-1. Modified with a C18 fatty di-acid chain attached via a spacer to the lysine at position 26, this modification enables extended half-life through albumin binding. Research has extensively studied its effects on glycemic control, appetite regulation, and body weight management.
These products are for laboratory research only and not intended for medical use. They must be handled by qualified professionals in controlled laboratory environments. This compound has not been evaluated by the FDA and is not approved for human or veterinary use.
These products are for laboratory research only and not intended for medical use. They must be handled by qualified professionals in controlled laboratory environments. This compound has not been evaluated by the FDA and is not approved for human or veterinary use.
This GLP-S is supplied as a lyophilized (freeze-dried) powder with a purity of ≥98% as determined by reverse-phase HPLC. Molecular identity is confirmed by mass spectrometry (ESI-MS). Each vial is accompanied by an analytical certificate of analysis (CoA). This product is formulated strictly for laboratory research use and is not sterile-filtered or prepared for administration to humans or animals.
Lyophilized GLP-S should be stored at −20°C in a desiccated environment, protected from light and moisture. Under these conditions, stability is maintained for up to 24 months from the date of manufacture. Once reconstituted, aliquots should be stored at −80°C and used within 30 days; repeated freeze-thaw cycles should be minimized to preserve peptide integrity.
For most in vitro applications, researchers typically reconstitute lyophilized GLP-S in sterile water or aqueous buffer (e.g., PBS, pH 7.4) at an initial stock concentration (e.g., 1 mg/mL), then further dilute into assay-appropriate media. Due to the fatty acid modification, addition of a small percentage of DMSO or use of carrier-supplemented buffer (e.g., 0.1% BSA in PBS) may improve solubility at higher concentrations. Reconstitution approaches should be optimized by the end-user laboratory for their specific assay system.
Published preclinical research has utilized GLP-S in diet-induced obese (DIO) rodent models, db/db diabetic mice, streptozotocin (STZ)-induced diabetic rats, and isolated human and rodent pancreatic islets. In vitro models include GLP1R-transfected HEK293 cells, INS-1E and MIN6 beta-cell lines, and primary neuronal cultures. These models have been used by independent research laboratories to probe receptor pharmacology, metabolic endpoints, and neurobiological signaling.
No. This GLP-S is supplied exclusively for in vitro and preclinical laboratory research purposes. It is not approved, tested, or intended for human administration, clinical trials, therapeutic use, or veterinary medical treatment. It does not meet the sterility, pyrogenicity, or regulatory standards required for any form of human or clinical use.
The primary molecular target investigated in GLP-S research is the glucagon-like peptide-1 receptor (GLP1R), a class B G-protein-coupled receptor (GPCR). Downstream research targets include adenylyl cyclase/cAMP signaling, PKA and EPAC pathways, PI3K/Akt, MAPK/ERK cascades, and transcription factors such as CREB and PDX-1. Research has also examined interactions with neuropeptide Y (NPY) circuitry and hypothalamic POMC neurons in preclinical feeding behavior models.
Scientific research has identified several key areas where GLP-S shows promising applications.
These research findings represent ongoing studies and should not be interpreted as medical claims or recommendations.
$99.00
